Radically changing immunotherapy by developing personalized treatments for inflammatory disease and cancer.

Our platform harnesses the potential of the immune system by empowering it to safely combat inflammatory disease and cancer. It is the first therapy to combine two anti-inflammatory cytokines for inflammatory disease, or to combine an immune stimulating cytokine and an anti-inflammatory cytokine into a single treatment for cancer. Through targeting, these powerful cytokine combinations enrich in the affected tissue with the potential to drive disease control.   

The Diakine™ platform is a next-generation cytokine therapy created to treat inflammatory disease and cancer based on each patient’s individual immune response.